Daniluromer

N/A

Report date: 2024/12/18 10:39:21
NMEFirst In Class

Base Information

Drug NameDaniluromer
Drug Alias NameEB-01
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhospholipases A2 inhibitors
TargetsPhospholipases A2
Therapy Area/IndicationsDermatitis, Allergic Contact
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesEdesa Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesEdesa Biotech Inc
Inactive CompaniesN/A
Active IndicationsDermatitis, Allergic Contact
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A